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Purpose: We examined the relationship between high myopia and common polymorphisms in four candidate genes:
collagen, type XI, alpha 1 (COL11A1); collagen, type XVIII, alpha 1 (COL18A1); fibrillin 1 (FBN1); and procollagen-
lysine 1,2-oxoglutarate 5-dioxygenase 1 (PLOD1). These genes were selected because rare pathogenic mutations in these
genes cause disease syndromes that have myopia, usually high myopia, as one of the common presenting features.
Methods: This study recruited 600 unrelated Han Chinese subjects including 300 cases with high myopia (spherical
equivalent or SE≤-8.00 diopters) and 300 controls (SE within ±1.00 diopter). A total of 66 tag single nucleotide
polymorphisms (SNPs) were selected for study from these four candidate genes. The study adopted a DNA pooling strategy
with an initial screen of DNA pools to identify putatively positive SNPs and then confirmed the “positive” SNPs by
genotyping individual samples forming the original DNA pools. DNA pools were each constructed by mixing equal
amounts of DNA from 50 individuals with the same phenotype status. Six case pools were prepared from 300 cases and
six control pools from 300 controls. Allele frequencies of DNA pools were estimated by analyzing the primer-extended
products with denaturing high performance liquid chromatography and compared between case pools and control pools
with nested ANOVA.
Results: In the first stage, 60 SNPs from the 4 candidate genes were successfully screened using the DNA pooling
approach. Of these, 6 SNPs showed a statistical significant difference in estimated allele frequencies between case pools
and controls at p<0.10. In the second stage, these “positive” SNPs were followed up by individual genotyping, but failed
to be confirmed via standard single-marker and haplotype analyses.
Conclusions: Common polymorphisms in these four candidate genes (COL11A1, COL18A1, FBN1 and PLOD1) were
unlikely to play important roles in the genetic susceptibility to high myopia.
Myopia is the commonest ocular disorder in the world.
In general, it is more prevalent in Oriental populations (60%–
80%) than in Caucasian populations (10%–25%) [1]. Subjects
with high myopia, usually defined as −6.0 diopters (D) or
worse, are more vulnerable to ocular pathologies later in their
life, such as cataract, glaucoma and retinal detachment [2].
Myopia is a complex disease with contribution from genetic
factors,  environmental  factors  and  their  interactions  [3,4].
Genetic  association  studies  are  usually  used  to  identify
myopia susceptibility genes, which tend to have small effect
size  [4,5].  Genome-wide  association  studies  generate
hypotheses for subsequent follow-up and are the method of
choice, but are still beyond the reach of many research groups
in terms of the cost. Another popular approach is to examine
candidate genes, which are usually selected on the basis of
their biology and function [4,6]. Genes underlying heritable
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disease  syndromes  with  myopia  as  one  of  the  common
presenting features can be selected as myopia candidate genes
for study [4,6].
Stickler  syndrome  is  an  autosomal  dominant  disease
affecting types II and XI collagen expressed in vitreous and
cartilage, and has highly variable clinical features affecting
the  eye,  the  ear  and  joints  [7,8].  In  particular,  Stickler
syndrome types 1 and 2 (STL1 and STL2) have myopia and
abnormal vitreous while type 3 is a non-ocular form of the
syndrome. STL1 is caused by mutations in the collagen, type
II, alpha 1 (COL2A1) gene while STL2 arises from mutations
in  the  collagen,  type  XI,  alpha  1  (COL11A1)  gene.
Interestingly, COL11A1 mutations are also known to cause
Marshall  syndrome  or  Marshall/Stickler  syndrome,  which
both  have  myopia  as  a  common  feature  [7,8].  Knobloch
syndrome is an autosomal recessive disease characterized by
high  myopia,  vitreoretinal  degeneration  and  occipital
encephalocele, and is caused by mutations in the collagen,
type  XVIII,  alpha  1  (COL18A1)  locus  [8-10].  Marfan
syndrome is an autosomal dominant disorder of connective
tissue with major manifestations affecting the ocular, skeletal
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810and  cardiovascular  systems  [11,12].  The  major  ocular
abnormalities are lens dislocation and high myopia due to
increased axial length. Marfan syndrome is classically caused
by mutations in the fibrillin 1 (FBN1) gene. Ehlers-Danlos
syndrome is a heterogeneous group of genetic disorders with
major clinical features of skin hyper-extensibility, atrophic
scarring, join hyper-mobility and generalized tissue fragility
[11]. Type VI or the kyphoscoliotic form of Ehlers-Danlos
syndrome is autosomal recessive in nature with added clinical
features of kyphoscoliosis (a form of curved spine) and scleral
fragility [11,12]. High myopia is also a common feature [13].
The  kyphoscoliotic  form  of  Ehlers-Danlos  syndrome  is
caused by mutations in the PLOD1 gene, which encodes the
enzyme procollagen-lysine 1,2-oxoglutarate 5 dioxygenase-1
(PLOD1; also known as lysyl hydroxylase 1) responsible for
forming  cross-links  in  collagens  via  hydroxylysine-based
pyridinoline.
The genes responsible for these syndromes are expressed
in  various  parts  of  the  eye.  These  disease  syndromes  are
caused by rare pathogenic loss-of-function mutations that are
not found in healthy individuals. The mechanisms leading to
the common occurrence of myopia, usually high myopia, in
these syndromes are not well established. We hypothesized
that  common  polymorphisms  in  these  genes  could  be
predisposing genetic factors for high myopia [4,6]. Indeed,
common polymorphisms in COL2A1 – the causative gene for
STL1 – have been found to be associated with myopia in two
family-based association studies [14,15]. In this study, we
evaluated COL11A1, COL18A1, FBN1, and PLOD1 (Table 1)
as candidate genes for high myopia in a Chinese population
with a case-control study approach.
We performed the study with an initial screen of DNA
pools  to  identify  putatively  positive  single  nucleotide
polymorphisms (SNPs) and then confirmed the “positive”
SNPs by genotyping individual samples forming the original
DNA pools. The initial screen of DNA pools was to cut down
the time and cost involved in sample-by-sample genotyping
[4,16]. DNA pools were constructed by mixing equal amounts
of DNA from many subjects with the same disease status. In
the  present  study,  “case  pools”  were  prepared  from
individuals with high myopia (cases) and “control pools” from
emmetropes (controls). Allele frequencies of DNA pools were
estimated by analyzing the primer-extended products with
denaturing  high  performance  liquid  chromatography
(DHPLC) [17] and compared between case pools and control
pools  with  a  proper  statistical  method,  nested  ANOVA
(ANOVA) [18].
METHODS
Subjects: This study recruited 600 unrelated Han Chinese
individuals including 300 cases with high myopia (spherical
equivalent or SE ≤-8.00 D for both eyes) and 300 control
subjects (SE within ±1.00 D for both eyes). The study was
approved by the Human Subjects Ethics Subcommittee of the
Hong Kong Polytechnic University and adhered to the tenets
of the Declaration of Helsinki. Written informed consents
were  obtained  from  all  participating  subjects.  Eye
examination  for  all  participants  was  conducted  in  the
Optometry  Clinic  of  the  University,  blood  samples  were
collected  and  DNA  was  extracted  as  has  been  described
previously [19]. Of particular relevance to this study was the
exclusion of subjects who showed obvious signs of ocular
disease  or  other  inherited  disease  associated  with  myopia
(e.g.,  Stickler  syndrome,  Marshall  syndrome,  Knobloch
syndrome, Marfan syndrome, Ehlers Danlos syndrome, etc).
Construction of DNA pools: A PicoGreen method (Invitrogen,
Carlsbad,  CA)  was  used  to  quantify  accurately  all  DNA
samples in accordance with the manufacturer’s protocols. The
DNA samples were then diluted to 5.0±0.3 ng/μl, and then
mixed in equal volumes to construct DNA pools. DNA from
50 distinct individuals sharing the same phenotype was mixed
to  construct  a  single  pool.  In  total,  six  case  pools  were
constructed from 300 cases, and six control pools from 300
controls.
Tag SNP selection: Four candidate genes were investigated in
this study: COL11A1, COL18A1, FBN1, and PLOD1 (Table
1). With the Tagger program [20], the following criteria were
used to select tag SNPs from each of the gene of interest and
its  adjoining  genomic  region  (3  kb  upstream  and  3  kb
downstream): pairwise tagging algorithm, r2≥0.8 and minor
allele frequency (MAF) ≥0.10. The Han Chinese genotype
data from the International HapMap Project database (release
23a, phase II) were used for tag SNP selection. In total, 66 tag
SNPs  were  selected  from  these  four  candidate  genes  and
screened by the DNA pooling strategy (Table 1).
Estimation of allele frequencies in DNA pools: Genomic DNA
(individual or pooled) was amplified for each SNP with a
touchdown  protocol  in  a  15-μl  reaction  mixture,  which
contained  0.1  or  0.3  μM  of  each  primer,  1.5  or  2.5  mM
TABLE 1. SUMMARY OF TAG SNPS IN THE COL11A1, COL18A1, FBN1, AND PLOD1 GENES.
Gene GeneID No. of exons Chromosmal
location
Region
captured
No. of tSNPs
selected
No. of SNPs captured
at mean r2=?
COL11A1 1301 68 1p21 238 kb 8 85 (r2=0.969)
COL18A1 80781 43 21q22.3 115 kb 30 81 (r2=0.956)
FBN1 2200 66 15q21.1 243 kb 19 142 (r2=0.925)
PLOD1 5351 19 1p36.22 47 kb 9 16 (r2=0.980)
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813MgCl2 (Table 2), 0.2 mM of each dNTP, 25 ng of DNA and
0.2  unit  of  DNA  polymerase  (HotStarTaq  Plus;  Qiagen,
Hilden,  Germany)  in  1×  PCR  buffer  supplied  by  the
manufacturer. All primers were designed using the OLIGO
software (version 6.57; Molecular Biology Insights, Cascade,
CO). A thermal cycler (GeneAmp PCR System 9700; Applied
Biosystems, Foster City, CA) was used for the touchdown
PCR: (1) initial denaturation of 5 min/95 °C; (2) 6 touchdown
cycles of 30 s/95 °C, 45 s/62 °C or 64 °C (initial annealing
temperature, Table 2) with a decrease of 1 °C per cycle, and
45 s/72 °C; (3) additional 38 cycles of 30 s/95 °C, 45 s/56 °C
or 58 °C (final target annealing temperature, Table 2), and 45
s/72 °C; and (4) final extension of 7 min/72 °C. PCR products
were then purified using exonuclease I (New England Biolabs,
Beverly,  MA)  and  shrimp  alkaline  phosphatase  (GE
Healthcare, Piscataway, NJ).
Primer extension (PE) reaction was performed in a 25-
μl reaction mixture, which contained 10 μl of purified PCR
product, 1.5 μM of a specific PE primer (Table 2), 50 μM of
each appropriate ddNTP (Table 2) and 1 unit of Therminator
(New England Biolabs, Beverly, MA) in a 1× reaction buffer
provided by the manufacturer. Amplification was conducted
as follows: initial denaturation of 1 min/96 °C, followed by
55 cycles of 10 s/96 °C, 15 s/43 °C and 1 min/60 °C. The
WAVE  Nucleic  Acid  Fragment  Analysis  System
(Transgenomic, Omaha, NE) was used for DHPLC analysis
of primer extended products. PE products were analyzed as
described previously [21] with the following modifications: a
6% linear gradient change of the working elution buffer over
a 3-min period and a different starting concentration of buffer
B, which varied with the SNP being studied (Table 2).
Estimation of the relative allele frequencies in DNA pools
was based on the peak heights of the PE products as analyzed
by DHPLC. Each DNA pool was analyzed in three replicates,
and each replicate consisted of a single PCR followed by a
single PE reaction and a single DHPLC analysis. Therefore,
each SNP had 36 sets of readings for 6 case pools and 6 control
pools.  For  each  SNP,  a  heterozygous  sample  was  first
identified by screening 10 to 40 subjects, and then analyzed
in three independent runs to obtain a mean value for the so-
called  “k  correction  factor”  that  was  used  to  correct  for
differential  incorporation  of  ddNTPs  in  PE  reactions  as
described previously [17].
Individual genotyping: The positive findings (6 SNPs) in the
initial screen of DNA pools were confirmed by genotyping
the individual samples that formed the original DNA pools.
The MassARRAY iPLEX Gold assay was used to genotype
the samples in accordance to the manufacturer’s protocols for
5 SNPs (Table 3). Because of the multiplexing format of the
MassARRAY  system,  these  SNPs  were  grouped  and
genotyped together with SNPs of other studies by a local
service provider. One SNP (rs2838922) could not be grouped
TABLE 3. PRIMERS FOR GENOTYPING INDIVIDUAL SAMPLES.
Gene, SNP Primer sequences (5′>3′)*
MassArray iPLEX Gold assay (Sequenom)
COL11A1, rs17127311 F: ACGTTGGATGCCTTTAGACTTCACATTCTC
  R: ACGTTGGATGGTATTAAGGAAAAAGCAAAGC
  PE primer: cccacGGAAAAAGCAAAGCAAAGTGATG
COL18A1, rs11911327 F: ACGTTGGATGTTTGCGTGGCTGCCTGGCCT
  R: ACGTTGGATGGACTCACAGATGCCTTTTGC
  PE primer: caTTCCCACAGCGCTGC
COL18A1, rs2236454 F: ACGTTGGATGCAGAAGCCAAGGACAGAAAC
  R: ACGTTGGATGATTGGGTCCGGACGGAATG
  PE primer: aaagcGATCCAGGAAACTCCCC
COL18A1, rs2236457 F: ACGTTGGATGGCTACAGGAGAGCACAGAAA
  R: ACGTTGGATGTCTATGACAGGAAAAGTCCC
  PE primer: aacaCCAAAATATACCACTTGGGG
COL18A1, rs2236475 F: ACGTTGGATGGCCAGTACCCAGGAGGAAG
  R: ACGTTGGATGTGACTGAGCCTAGCACACAC
  PE primer: ggacGGCCCACTGCCCTGTCTGCC
Restriction fragment length polymorphism
COL18A1, rs2838922 F: CTGCTTCCCCACCTTTTCAC
  R: (T)20 CTGAGATGTGAGAATCGCTCGA
        *F=forward primer; R=reverse primer; and PE=primer extension. Note that bases in lower case are added to the PE primers to
        allow better size discrimination of the primer extended products in the multiplex assays of the MassARRAY system.
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814together with other SNPs for the MassARRAY system, and
was genotyped by the method of restriction fragment length
polymorphism (Table 3). The fragment was amplified using
touchdown  PCR  as  described  above  with  the  following
specific conditions: 0.1 μM of each primer, 1.5 mM MgCl2,
64 °C as the initial annealing temperature and 58 °C as the
final target annealing temperature. Overnight digestion of the
PCR  products  by  TaqI  (Fermentas,  Vilnius,  Lithuania)  at
65  °C  was  performed  according  to  the  manufacturer’s
instructions.  Digested  products  were  separated  by
electrophoresis in polyacrylamide gels.
Statistical  analysis:  Ocular  data  were  analyzed  with  the
STATA package (version 8.2; StataCorp, College Station,
TX). Subjects were classified as cases (affected with high
myopia) or controls (unaffected). For a given SNP, the relative
allele frequencies were estimated from the peak heights of the
two extension products and adjusted using the k correction
factor according to the method reported by Hoogendoorn et
al. [17]. With the STATA package, nested ANOVA [18] was
used to compare the relative allele frequencies of the case
pools  and  the  control  pools.  A  p  value  ≤0.10  for  the
comparison between case pools and control pools was used as
the  threshold  for  following  up  SNPs  with  individual
genotyping. Genotype data of individual samples were tested
for  Hardy–Weinberg  equilibrium  (HWE),  and  compared
between  cases  and  controls  for  association.  The  PLINK
package (version 1.07) [22] was used for analysis. The linkage
disequilibrium measures were calculated and plotted using
Haploview  (version  4.2)  [23].  Haplotype  blocks  were
constructed using the algorithm known as the solid spine of
LD,  which  is  unique  to  Haploview.  Potential  interactions
among SNPs were examined using the method of multifactor
dimensionality reduction (MDR) [24].
RESULTS
Analysis  of  the  ocular  data:  The  characteristics  of  the
participating  subjects  have  been  reported  in  one  of  our
previous studies [19]. They are briefly summarized as follows.
The average SE was −10.53 (range: −24.00 to −8.00) D for
cases, and 0.03 (range: −1.00 to 0.88) D for controls. The
average axial length was 27.76 (range: 24.62 – 31.29) mm for
cases, and 23.85 (range: 21.24 to 27.71) mm for controls.
These ocular data are for the right eyes. The average age was
27.7 (range: 15 to 48) years for cases, and 24.9 (range: 17 to
46) years for controls. There were more male subjects in the
control  group  than  in  the  case  group  (43.7%  vs  28.3%,
p=4.30×10−5).
Analysis of results for DNA pools: The results are summarized
in Table 4. Of the 66 tag SNPs selected for study, 6 did not
give any results because of failure in PCR or PE even after
repeated optimization as noted in a footnote of Table 2. For
the 60 SNPs successfully analyzed, the k correction factor
ranged from 0.29 to 1.56 with a mean of 1.02; it ranged from
0.83 to 1.21 for 54 SNPs (90% of the SNPs analyzed). The
estimated frequencies of the first eluted alleles ranged from
0.1041 to 0.9246 for case pools, and from 0.0929 to 0.9516
for control pools. The difference (case pools – control pools)
in estimated allele frequencies varied from −0.0510 to 0.0337.
At a lenient threshold of p≤0.10, six SNPs gave significant
results, which were followed up with individual genotyping
for confirmation. These included one SNP in the COL11A1
gene: rs17127311 (difference=-0.0325, p=0.0981). The other
five “positive” SNPs were in the COL18A1 gene: rs2838922
(difference=0.0367,  p=0.0572),  rs11911327
(difference=-0.0315,  p=0.0959),  rs2236454
(difference=-0.0510,  p=0.0629),  rs2236457
(difference=0.0255,  p=0.0779),  and  rs2236475
(difference=-0.0367, p=0.0852). No significant difference in
allele  frequencies  was  demonstrated  in  the  remaining  55
SNPs, which were thus not tested any further.
Confirmation  of  pooled  DNA  results  by  individual
genotyping: The genotypes of these six SNPs were in HWE
except two SNPs (rs2838922 and rs223475) in cases and two
SNPs  (rs17127311  and  rs2838922)  in  controls  (Table  5).
Deviation from HWE in cases can be a signal for SNP-disease
association [25]. The two SNPs violating HWE in controls
(rs17127311 and rs2838922) were dropped from subsequent
analysis. One haplotype block was constructed for three SNPs
as  shown  in  Figure  1.  All  four  SNPs  were  analyzed  for
association with high myopia with adjustment for gender, but
did  not  show  significant  differences  in  allele  frequencies
between cases and controls (Table 5). Sliding window-based
haplotype  analysis  of  these  four  SNPs  (rs11911327  [S1],
rs2236454 [S2], rs2236457 [S3], and rs2236475 [S4] in the
5′>3′ order along the sense strand of the COL18A1 gene) did
not show any association with high myopia either. The p
values for the omnibus tests of haplotypes adjusted for gender
were as follows: 0.2000 (S1-S2), 0.2850 (S2-S3), 0.1860 (S3-
S4), 0.2560 (S1-S2-S3), 0.1840 (S2-S3-S4), and 0.2810 (S1-
S2-S3-S4). MDR did not show any significant interaction
among the SNPs either, with the best model consisting of all
four SNPs (p=0.1719).
DISCUSSION
This  study  explored  the  relationship  of  common
polymorphisms  in  four  candidate  genes  (COL11A1,
COL18A1, FBN1, and PLOD1) with high myopia in a Han
Chinese  population.  Rare  pathogenic  mutations  in  these
candidate genes cause disease syndromes that have myopia,
usually  high  myopia,  as  one  of  the  common  presenting
features [8-13]. It was logical to investigate whether common
polymorphisms of these genes would be predisposing genetic
factors for high myopia. This argument was strengthened by
the positive association between common polymorphisms of
the COL2A1 gene, the causative gene underlying STL1, and
myopia  [14,15].  The  relationship  between  the  selected
candidate genes and high myopia has not been studied before.
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817With this background, we examined these candidate gene
with an efficient approach based on the initial screening of
DNA  pools.  Six  case  pools  and  six  control  pools  were
constructed  and  screened  by  DHPLC  analysis  of  primer
extended products. Our case subjects were recruited with a
refractive error (SE) threshold of at least −8.00 D for both
eyes, and the average SE was −10.53 D. Such a high threshold
was adopted for case subject recruitment so as to enrich the
contribution of genetic factors to the extreme phenotype and
to enhance the homogeneity of the case phenotype [4,6]. Our
control subjects were emmetropic and were not randomly
recruited from the general Chinese population in Hong Kong.
This  would  also  enhance  the  difference  in  the  genetic
components contributing to the phenotype difference between
our cases and controls. Random population-based controls
were  less  desirable  because  they  would  be  enriched  with
subjects with mild  to moderate myopia from our population
– a population with a high prevalence of myopia [26]. These
strategies would enhance the power of our study.
In the first stage, 60 SNPs from the 4 candidate genes
were successfully screened using the DNA pooling approach.
Of these, 6 SNPs gave a p value of less than 0.10 for the
statistical comparison of allele frequency differences between
case pools and control pools by nested ANOVA (Table 4). A
TABLE 5. ALLELIC ASSOCIATION TESTS OF COL11A1 AND COL18A1 SNPS GENOTYPED INDIVIDUALLY.
  Alleles* Genotype counts (11/12/22)* HWE test (p value) Minor allele freq Allelic test†
SNP 1 2 Cases Controls Cases Controls Cases Controls OR (95% CI) p value
COL11A1
rs17127311 A G 206/74/5 165/89/2 0.8128 0.0054 0.1474 0.1816 – ‡ – ‡
COL18A1
rs2838922 C T 197/75/26 174/91/28 4.47E-05 0.0047 0.2131 0.2509 – ‡ – ‡
rs11911327 C T 197/89/10 192/97/7 1.0000 0.2524 0.1841 0.1875 0.98 (0.72 - 1.33) 0.8979
rs2236454 C T 74/131/90 79/144/73 0.0621 0.6431 0.5271 0.4899 1.15 (0.92 - 1.44) 0.2132
rs2236457 C T 183/94/22 180/93/14 0.0508 0.7221 0.2308 0.2108 1.10 (0.84 - 1.44) 0.5011
rs2236475 A G 184/88/22 176/96/21 0.0187 0.1427 0.2245 0.2355 0.93 (0.71 - 1.20) 0.5672
        *The major allele is designated as “1” and minor allele as “2”; and the genotype counts are indicated as the counts of the
        genotypes 11, 12, and 22, respectively. This study had 300 cases and 300 controls. Note that the total genotype counts may not
        add up to these expected numbers because a few samples failed to be genotyped in a random fashion. †The allelic test is performed
        with the gender as a covariate to adjust for the potential confounding by gender because the cases and controls differ significantly
        in the proportions of male and female subjects (p=4.30×10–5).The odds ratio (OR) is calculated for the minor allele (allele 2)
        with the major allele (allele 1) as the reference. ‡ Association tests are not performed for these two SNPs (rs17127311 and
        rs2838922) because the genotypes in the controls are not in Hardy–Weinberg equilibrium (HWE).
Figure  1.  Single  nucleotide
polymorphisms  (SNPs)  and  their
linkage  disequilibrium  (LD)  for  the
COL18A1 gene. The SNPs are indicated
from the 5′ end (left) to the 3′ end (right)
of  the  gene.  The  LD  measures  are
expressed as D’ and r2 for all subjects
under  study  (cases  and  controls
combined),  and  are  calculated  by
Haploview. The shades of red (for D’)
and gray (for r2) represent the magnitude
of the measures with deep red equal to
100% (or 1.00), which is omitted in the
diagram to avoid cluttering.
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818lenient significance threshold of p≤0.10 was used to avoid
missing potentially significant SNPs. In the second stage,
these  “positive”  SNPs  were  followed  up  by  individual
genotyping, but failed to be confirmed via standard single-
marker  (Table  5)  and  haplotype  analyses.  In  conclusion,
common  polymorphisms  in  these  four  candidate  genes
(COL11A1, COL18A1, FBN1, and PLOD1) were unlikely to
play  important  roles  in  the  genetic  susceptibility  to  high
myopia.
It is interesting to note that deviations from HWE were
observed in the control group for two SNPs (rs17127311 and
rs2838922; Table 5). The Hardy–Weinberg principle assumes
a very large population in which mating is random and there
are  no  migration,  mutation  and  natural  selection  [27].
Theoretically, violations of these assumptions can result in
deviations from HWE. However, deviations from HWE can
indicate the presence of genotyping errors [28]. We had been
very careful in carrying out the genotyping and calling the
genotypes, and we confirmed any ambiguous genotypes by
direct DNA sequencing. However, we cannot entirely rule out
the possibility of genotyping errors as a cause for deviations
from HWE. It is generally recommended not to perform case-
control comparison for such genotype data to avoid false
positive association results [28].
We used nested ANOVA [18] to test for differences in
estimated allele frequencies between case pools and control
pools.  Nested  ANOVA  can  properly  handle  the  variance
components of the errors arising from sampling of the subjects
in forming the pools and of the technical errors arising from
various stages of allele frequency estimation, e.g., unequal
amounts of individual DNA samples in forming the pools,
errors in PCR and primer extension reaction, and in DHPLC
analysis. However, the individual variance components could
not be estimated directly. Thus, it was not possible to calculate
the power of our DNA pooling based-approach, which would
expectedly be less than the power of an approach based on
genotyping of all individual samples for all tag SNPs. In
addition, our DNA pooling strategy did not allow haplotype
analysis for SNPs only examined for the DNA pools [16]. On
the other hand, we enhanced the power of our study by using
stringent criteria for recruiting the cases (extreme phenotype)
and the controls (supernormal), as has been discussed above
[4,6,26].
DNA pooling has been proven to be effective as an initial
screen  of  SNPs  to  search  for  putative  genetic  markers
associated with a phenotype of interest for subsequent follow-
up studies based on conventional genotyping of individual
samples [16,29]. Saving in the amounts of DNA used and in
the  cost  and  time  involved  in  genotyping  is  the  major
advantage of DNA pooling. For each SNP, 36 separate PCRs
and the following analyses were needed for 6 case pools and
6 control pools together with 3 other separate PCRs for a
heterozygous sample to determine the k correction factor. In
comparison  to  genotyping  600  samples  individually,  our
current DNA pooling approach could theoretically reduce the
amounts of DNA used and the genotyping work by up to
93.5%. Note that we mixed DNA from 50 distinct individuals
to form one DNA pool. This approach of using more pools of
smaller size has been shown to be superior to the use of fewer
DNA pools each formed from a larger number of subjects for
genetic association studies of candidate genes [30].
It  may  seem  that  DNA  pooling  may  become  less
attractive with the recent tremendous reduction in the unit cost
of  genotyping  for  high-throughput  array-based  whole-
genome genotyping assays. However, the total cost of such
genome-wide genotyping is still too expensive and hence
unaffordable for most research groups. Use of DNA pools for
genome-wide genotyping is one of the solutions proposed
[31]. Recent studies even suggest the use of DNA pools for
deep  sequencing  using  next-generation  sequencing
technologies to explore the role of rare variants in complex
diseases [32,33] because both common and rare variants are
believed to contribute to the genetic susceptibility to complex
diseases [34]. This new development is particularly important
because  deep  sequencing  is  even  more  expensive  and
produces  even  larger  amounts  of  data  for  analysis  than
genome-wide genotyping. Note that the present study did not
address the potential role of rare variants that may contribute
to the genetic susceptibility to high myopia, but do not cause
the  respective  Mendelian  disease  syndromes  mentioned
above. Indeed, there are already rare variants reported to be
associated with high myopia but not congenital stationary
night  blindness  ([35]  and  unpublished  data).  Congenital
stationary night blindness is an X-linked monogenic ocular
disease with high myopia as one of its common presenting
features [36].
In  summary,  we  examined  using  a  DNA  pooling
approach tag SNPs from four candidate genes (COL11A1,
COL18A1, FBN1, and PLOD1) selected because pathogenic
mutations in these genes cause disease syndromes that have
myopia,  usually  high  myopia,  as  one  of  the  common
presenting clinical features. Six SNPs were followed up by
individual  genotyping,  but  did  not  demonstrate  any
association with high myopia. We concluded that common
polymorphisms in these candidate genes were unlikely to be
important in the genetic susceptibility to high myopia in Han
Chinese.
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